Literature DB >> 23507275

Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis.

Kristina Shigyo1, Oksana Ocheretina, Yves Mary Merveille, Warren D Johnson, Jean William Pape, Carl F Nathan, Daniel W Fitzgerald.   

Abstract

Nitazoxanide (NTZ) has bactericidal activity against the H37Rv laboratory strain of Mycobacterium tuberculosis with a MIC of 16 μg/ml. However, its efficacy against clinical isolates of M. tuberculosis has not been determined. We found that NTZ's MIC against 50 clinical isolates ranged from 12 to 28 μg/ml with a median of 16 μg/ml and was unaffected by resistance to first- or second-line antituberculosis drugs or a diversity of spoligotypes.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23507275      PMCID： PMC3716123          DOI： 10.1128/AAC.02542-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  33 in total

1.  XDR tuberculosis--implications for global public health.

Authors:  Mario C Raviglione; Ian M Smith
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

2.  Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent.

Authors:  Saima Aslam; Daniel M Musher
Journal:  Future Microbiol       Date:  2007-12       Impact factor: 3.165

3.  Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide.

Authors:  J F Rossignol; A Ayoub; M S Ayers
Journal:  J Infect Dis       Date:  2001-05-29       Impact factor: 5.226

4.  The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation.

Authors:  Menashe Elazar; Michael Liu; Sean A McKenna; Ping Liu; Elizabeth A Gehrig; Joseph D Puglisi; Jean-François Rossignol; Jeffrey S Glenn
Journal:  Gastroenterology       Date:  2009-08-04       Impact factor: 22.682

Review 5.  A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis.

Authors:  Carl Nathan; Ben Gold; Gang Lin; Melanie Stegman; Luiz Pedro Sorio de Carvalho; Omar Vandal; Aditya Venugopal; Ruslana Bryk
Journal:  Tuberculosis (Edinb)       Date:  2008-08       Impact factor: 3.131

6.  Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4.

Authors:  J F Rossignol; S M Kabil; Y El-Gohary; A Elfert; E B Keeffe
Journal:  Aliment Pharmacol Ther       Date:  2008-06-26       Impact factor: 8.171

7.  Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d.

Authors:  A Stockis; S De Bruyn; C Gengler; D Rosillon
Journal:  Int J Clin Pharmacol Ther       Date:  2002-05       Impact factor: 1.366

8.  Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance.

Authors:  Luiz Pedro S de Carvalho; Gang Lin; Xiuju Jiang; Carl Nathan
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

9.  Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.

Authors:  Brent E Korba; Menashe Elazar; Ping Lui; Jean-François Rossignol; Jeffrey S Glenn
Journal:  Antimicrob Agents Chemother       Date:  2008-08-18       Impact factor: 5.191

10.  Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis.

Authors:  Karen K Y Lam; Xingji Zheng; Roberto Forestieri; Aruna D Balgi; Matt Nodwell; Sarah Vollett; Hilary J Anderson; Raymond J Andersen; Yossef Av-Gay; Michel Roberge
Journal:  PLoS Pathog       Date:  2012-05-10       Impact factor: 6.823
View more
  16 in total

1.  Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Authors:  Joseph S Cavanaugh; Ruwen Jou; Mei-Hua Wu; Tracy Dalton; Ekaterina Kurbatova; Julia Ershova; J Peter Cegielski
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

2.  Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture.

Authors:  Elizabeth P Harausz; Keith A Chervenak; Caryn E Good; Michael R Jacobs; Robert S Wallis; Manuel Sanchez-Felix; W Henry Boom
Journal:  Tuberculosis (Edinb)       Date:  2016-03-22       Impact factor: 3.131

3.  Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.

Authors:  Kohta Saito; Thulasi Warrier; Selin Somersan-Karakaya; Lina Kaminski; Jianjie Mi; Xiuju Jiang; Suna Park; Kristi Shigyo; Ben Gold; Julia Roberts; Elaina Weber; William R Jacobs; Carl F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

Review 4.  New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.

Authors:  Thomas R Hawn; Javeed A Shah; Daniel Kalman
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

5.  Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis.

Authors:  K F Walsh; K McAulay; M H Lee; S C Vilbrun; L Mathurin; D Jean Francois; M Zimmerman; F Kaya; N Zhang; K Saito; O Ocheretina; R Savic; V Dartois; W D Johnson; J W Pape; C Nathan; D W Fitzgerald
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.938

Review 6.  The present state of the tuberculosis drug development pipeline.

Authors:  M Daben J Libardo; Helena Im Boshoff; Clifton E Barry
Journal:  Curr Opin Pharmacol       Date:  2018-08-23       Impact factor: 5.547

7.  Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori.

Authors:  Paul S Hoffman; Alexandra M Bruce; Igor Olekhnovich; Cirle A Warren; Stacey L Burgess; Raquel Hontecillas; Monica Viladomiu; Josep Bassaganya-Riera; Richard L Guerrant; Timothy L Macdonald
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

8.  Antiinfectives targeting enzymes and the proton motive force.

Authors:  Xinxin Feng; Wei Zhu; Lici A Schurig-Briccio; Steffen Lindert; Carolyn Shoen; Reese Hitchings; Jikun Li; Yang Wang; Noman Baig; Tianhui Zhou; Boo Kyung Kim; Dean C Crick; Michael Cynamon; J Andrew McCammon; Robert B Gennis; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

9.  Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.

Authors:  Ben Gold; Julia Roberts; Yan Ling; Landys Lopez Quezada; Jou Glasheen; Elaine Ballinger; Selin Somersan-Karakaya; Thulasi Warrier; J David Warren; Carl Nathan
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

10.  Nitazoxanide is active against Mycobacterium leprae.

Authors:  Mai Ann Bailey; Hana Na; Malcolm S Duthie; Thomas P Gillis; Ramanuj Lahiri; Tanya Parish
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.